Trends in breast cancer incidence and mortality in France 1990-2008

Breast Cancer Research and Treatment

Volumn 147, Issue 1, 2014, Pages 167-175

  Molinie F ^a,n   Vanier, A ^b,c,d   Woronoff, A S ^e,n   Guizard, A V ^f,n   Delafosse, P ^g,n   Velten, M ^h,i,n   Daubisse Marliac, L ^j,k,n   Arveux, P ^l,n   Tretarre, B ^m,n  

^a Registre des Cancers de Loire Atlantique/Vendée ^*  (France)

^b SORBONNE UNIVERSITÉ   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d UNIVERSITÉ DE NANTES   (France)

^e Registre des cancers du Doubs   (France)

^f Registre des cancers du Calvados   (France)

^g Registre des Cancers de l'Isère   (France)

^h Registre des cancers du Bas Rhin   (France)

ⁱ Regional Paul Strauss Cancer Centre   (France)

^j Registre des Cancers du Tarn   (France)

^k INSTITUT CLAUDIUS REGAUD   (France)

^l Registre des cancers du sein et des cancers gynécologiques de Côte d Or   (France)

^m Centre de Recherche   (France)

ⁿ Network of French Cancer Registries (FRANCIM)   (France)

more..

Author keywords

Breast cancer; Ductal carcinoma in situ; Epidemiology; Incidence; Mortality; Population based registries

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGISTRY; CANCER SCREENING; FEMALE; FRANCE; HUMAN; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MIDDLE AGED; POPULATION RESEARCH; PRIORITY JOURNAL; BREAST NEOPLASMS; CANCER STAGING; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FOLLOW UP; INCIDENCE; MORTALITY; PATHOLOGY; PROGNOSIS; REGISTER; SURVIVAL RATE; TIME; TRENDS; TUMOR INVASION; YOUNG ADULT;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; FOLLOW-UP STUDIES; FRANCE; HUMANS; INCIDENCE; MIDDLE AGED; MORTALITY; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; REGISTRIES; SURVIVAL RATE; TIME FACTORS; YOUNG ADULT;

EID: 84906055525     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-3073-9     Document Type: Article

References (44)

1. Forouzanfar MH, Foreman KJ, Delossantos AM et al (2011) Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet 378:1461-1484. doi:10.1016/S0140-6736(11)61351-2
2. Glass AG, Lacey JV Jr, Carreon JD, Hoover RN (2007) Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 99:1152-1161. doi:10.1093/jnci/djm059
3. Weedon-Fekjær H, Bakken K, Vatten LJ, Tretli S (2012) Understanding recent trends in incidence of invasive breast cancer in Norway: age-period-cohort analysis based on registry data on mammography screening and hormone treatment use. BMJ 344:e299
4. Key TJ, Verkasalo PK, Banks E (2001) Epidemiology of breast cancer. Lancet Oncol 2:133-140. doi:10.1016/S1470-2045(00)00254-0
5. Bulletin Officiel No. 2001-43. http://www.sante.gouv.fr/fichiers/bo/2001/ 01-43/a0432846.htm. Accessed Nov 25 2013
6. Duport N (2012) Characteristics of women using organized or opportunistic breast cancer screening in France.Analysis of the 2006 French Health, Health Care and Insurance Survey. Rev Epidémiol Sante Publique 60:421-430. doi:10.1016/j.respe.2012.05.006
7. European Network of Cancer Registries, Tyczyński JE, Démaret E, et al (2003) Standards and guidelines for cancer registration in Europe: the ENCR recommendations: volume I. International Agency for Research on Cancer, Lyon
8. R Development Core Team (2010) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna
9. Belot A, Grosclaude P, Bossard N et al (2008) Cancer incidence and mortality in France over the period 1980-2005. Rev Epidémiologie Santé Publique 56:159-175. doi:10.1016/j.respe. 2008.03.117
10. Lacour A, Mamelle N, Arnold F et al (1997) Mass screening programs for breast cancer in France. Comparative evaluation. J Gynécologie Obstétrique Biol Reprod 26:470-483
11. Puliti D, Duffy SW, Miccinesi G et al (2012) Overdiagnosis in mammographic screening for breast cancer in Europe: a literature review. J Med Screen 19(Suppl 1):42-56. doi:10.1258/jms.2012.012082
12. Marmot MG (2013) Sorting through the arguments on breast screening. JAMA 309:2553-2554. doi:10.1001/jama.2013.6822
13. Wu D, Pérez A (2011) A limited review of over diagnosis methods and long term effects in breast cancer screening. Oncol Rev 5:143-147. doi:10.1007/s12156-011-0077-0
14. De Gelder R, Heijnsdijk EAM, van Ravesteyn NT et al (2011) Interpreting overdiagnosis estimates in population-based mammography screening. Epidemiol Rev 33:111-121. doi:10.1093/epirev/mxr009
15. Daubisse-Marliac L, Delafosse P, Boitard JB et al (2011) Breast cancer incidence and time trend in France from 1990 to 2007: a population-based study from two French cancer registries. Ann Oncol 22:329-334. doi:10.1093/annonc/ mdq396
16. Ravdin PM, Cronin KA, Howlader N et al (2007) The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356:1670-1674. doi:10.1056/NEJMsr070105
17. Zbuk K, Anand SS (2012) Declining incidence of breast cancer after decreased use of hormone-replacement therapy: magnitude and time lags in different countries. J Epidemiol Community Health 66:1-7. doi:10.1136/jech.2008. 083774
18. Gompel A, Plu-Bureau G (2010) Is the decrease in breast cancer incidence related to a decrease in postmenopausal hormone therapy? Ann N Y Acad Sci 1205:268-276. doi:10.1111/j.1749-6632.2010.05664.x
19. Jemal A, Ward E, Thun MJ (2007) Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res 9:R28. doi:10.1186/bcr1672
20. Séradour B, Allemand H, Weill A, Ricordeau P (2009) Changes by age in breast cancer incidence, mammography screening and hormone therapy use in France from 2000 to 2006. Bull Cancer 96:E1-E6. doi:10.1684/bdc.2009.0869
21. Dietel M, Lewis MA, Shapiro S (2005) Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a minireview. Hum Reprod (Oxford, England) 20:2052-2060. doi:10.1093/humrep/dei043
22. Hill C, Laplanche A (2010) La consommation d'alcool est tropélevée en France. Presse Médicale 39:e158-e164. doi:10.1016/j.lpm.2009.12.010
23. Leclère B, Molinié F, Trétarre B et al (2013) Trends in incidence of breast cancer among women under 40 in seven European countries: a GRELL cooperative study. Cancer Epidemiol 37:544-549. doi:10.1016/j.canep. 2013.05.001
24. Sørum R, Hofvind S, Skaane P, Haldorsen T (2010) Trends in incidence of ductal carcinoma in situ: the effect of a population-based screening programme. Breast (Edinburgh, Scotland) 19:499-505. doi:10.1016/j.breast.2010.05.014
25. Virnig BA, Wang S-Y, Shamilyan T et al (2010) Ductal carcinoma in situ: risk factors and impact of screening. JNCI Monogr 2010:113-116. doi:10.1093/jncimonographs/lgq024
26. Toriola AT, Colditz GA (2013) Trends in breast cancer incidence and mortality in the United States: implications for prevention. Breast Cancer Res Treat 138:665-673. doi:10.1007/s10549-013-2500-7
27. Kumar AS, Bhatia V, Henderson IC (2005) Overdiagnosis and overtreatment of breast cancer: rates of ductal carcinoma in situ: a US perspective. Breast Cancer Res 7:271-275. doi:10.1186/bcr1346
28. Autier P, Boniol M, La Vecchia C et al (2010) Disparities in breast cancer mortality trends between 30 European countries: retrospective trend analysis of WHO mortality database. BMJ 341:c3620. doi:10.1136/bmj.c3620
29. Broeders M, Moss S, Nyström L et al (2012) The impact of mammographic screening on breast cancer mortality in Europe: a review of observational studies. J Med Screen 19(Suppl 1):14-25. doi:10.1258/jms.2012. 012078
30. Independent UK Panel (2012) The benefits and harms of breast cancer screening: an independent review. Lancet 380:1778-1786. doi:10.1016/S0140- 6736(12)61611-0
31. Gøtzsche PC, Nielsen M (2011) Screening for breast cancer with mammography. Cochrane Database Syst Rev (1):CD001877. doi:10.1002/14651858. CD001877.pub4
32. Kalager M, Zelen M, Langmark F, Adami H-O (2010) Effect of screening mammography on breast-cancer mortality in Norway. N Engl J Med 363:1203-1210. doi:10.1056/NEJMoa1000727
33. Blanks RG, Moss SM, McGahan CE et al (2000) Effect of NHS breast screening programme on mortality from breast cancer in England and Wales, 1990-8: comparison of observed with predicted mortality. BMJ 321:665-669
34. Olsen AH, Njor SH, Lynge E (2007) Estimating the benefits of mammography screening: the impact of study design. Epidemiology (Cambridge, Mass.) 18:487-492. doi:10.1097/EDE.0b013e318060cbbd
35. Moss SM, Nyström L, Jonsson H et al (2012) The impact of mammographic screening on breast cancer mortality in Europe: a review of trend studies. J Med Screen 19(Suppl 1):26-32. doi:10.1258/jms.2012.012079
36. Hanley JA (2011) Measuring mortality reductions in cancer screening trials. Epidemiol Rev 33:36-45. doi:10.1093/epirev/mxq021
37. Berry DA, Cronin KA, Plevritis SK et al (2005) Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353:1784-1792. doi:10.1056/NEJMoa050518
38. Vilaprinyo E, Puig T, Rue M (2012) Contribution of early detection and adjuvant treatments to breast cancer mortality reduction in Catalonia, Spain. PLoS One 7:e30157. doi:10.1371/journal.pone.0030157
39. Lee S, Zelen M (2006) A stochastic model for predicting the mortality of breast cancer. J Natl Cancer Inst Monogr (36):79-86. doi:10.1093/jncimonographs/ lgj011
40. Mandelblatt J, Schechter CB, Lawrence W, et al (2006) The SPECTRUM population model of the impact of screening and treatment on U.S. breast cancer trends from 1975 to 2000: principles and practice of the model methods. J Natl Cancer Inst Monogr (36):47-55. doi:10.1093/jncimonographs/lgj008
41. Youlden DR, Cramb SM, Dunn NAM et al (2012) The descriptive epidemiology of female breast cancer: an international comparison of screening, incidence, survival and mortality. Cancer Epidemiol 36:237-248. doi:10.1016/j.canep.2012. 02.007
42. Uhry Z, Hédelin G, Colonna M et al (2011) Modelling the effect of breast cancer screening on related mortality using French data. Cancer Epidemiol 35:235-242. doi:10.1016/j.canep.2010.10.009
43. Sprague BL, Trentham-Dietz A, Remington PL (2011) The contribution of postmenopausal hormone use cessation to the declining incidence of breast cancer. Cancer Causes Control CCC 22:125-134. doi:10.1007/s10552-010-9682-7
44. Ringa V, Fournier A (2008) Did the decrease in use of menopausal hormone therapy induce a decrease in the incidence of breast cancer in France (and elsewhere)? Rev Epidémiologie Santé Publique 56:297-301. doi:10.1016/j.respe.2008.07.085